15 results on '"Contardo V"'
Search Results
2. PIN16 - Caracterización Clínica Y Económica De Hospitalización Por Varicela En Niños En La Región Metropolitana Y Región De Valparaíso, Chile
- Author
-
Torres, JP, De la Maza, V, Castro, M, Conca, N, Izquierdo, G, Suau, T, Rodriguez, P, Contardo, V, Rosales, A, and Ducasse, K
- Published
- 2017
- Full Text
- View/download PDF
3. Epidemiological changes of invasive fungal disease in children with cancer: Prospective study of the National Child Program of Antineoplastic Drugs network, Chile.
- Author
-
Barraza M, Valenzuela R, Villarroel M, de la Maza V, Contardo V, Álvarez AM, Gutiérrez V, Zubieta M, Martínez D, and Santolaya ME
- Subjects
- Humans, Chile epidemiology, Male, Prospective Studies, Child, Female, Child, Preschool, Incidence, Immunocompromised Host, Adolescent, Infant, Antineoplastic Agents therapeutic use, Invasive Fungal Infections epidemiology, Invasive Fungal Infections drug therapy, Neoplasms epidemiology, Neoplasms complications
- Abstract
Background: Invasive fungal diseases (IFD) are high morbidity and mortality infections in children with cancer suffering episodes of high-risk febrile neutropenia (HRFN). IFD epidemiology has changed in the last two decades, with an increasing incidence in recent years due to the growing number of immunocompromised children at risk for IFD. The aim of this study was to evaluate the incidence of IFD in children with cancer in the period 2016-2020 compared to 2004-2006 in six hospitals in Chile., Methods: Prospective, multicentre study, carried out between 2016 and 2020 in six hospitals in Chile. The defined cohort corresponds to a dynamic group of HRFN episodes in patients <18 years old with cancer, who at the fourth day of evolution still presented fever and neutropenia (persistent HRFN). Each episode was followed until resolution of FN. The incidence of IFD was calculated between 2016 and 2020 and compared with data obtained in the period 2004-2006. The incidence rate was estimated., Results: A total of 777 episodes of HRFN were analysed; 257 (33.1%) were considered as persistent-HRFN occurring in 174 patients. The median age was 7 years (IQR: 3-12 years) and 52.3% (N = 91) were male. Fifty-three episodes of IFD were detected: 21 proven, 14 probable and 18 possible. Possible IFD were excluded, leaving 239 episodes of persistent-HRFN with an IFD incidence of 14.6% (95% CI 10.5-19.9) and an incidence rate of 13.6 IFD cases per 1000 days of neutropenia (95% CI 9.5-20.0). Compared to 2004-2006 cohort (incidence: 8.5% (95% CI 5.2-13.5)), a significant increase in incidence of 6.1% (95% CI 0.2-12.1, p = .047) was detected in cohorts between 2016 and 2020., Conclusion: We observed a significant increase in IFD in 2016-2020, compared to 2004-2006 period., (© 2024 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
4. Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial.
- Author
-
Torres JP, Ibañez C, Valenzuela R, Rivera S, De la Maza V, Villarroel M, Coria P, Contardo V, Álvarez AM, Zubieta CM, Gutierrez V, Ducasse K, Martínez D, and Santolaya ME
- Subjects
- Humans, Male, Female, Child, Child, Preschool, Prospective Studies, Chile, Febrile Neutropenia drug therapy, Infant, Withholding Treatment, Fever drug therapy, Treatment Outcome, Anti-Infective Agents therapeutic use, Anti-Infective Agents administration & dosage, Anti-Infective Agents adverse effects, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Hospitalization, Adolescent, Respiratory Tract Infections drug therapy, Respiratory Tract Infections virology, Virus Diseases drug therapy, Neoplasms drug therapy, Neoplasms complications
- Abstract
Objectives: To validate the efficacy and safety of withholding antimicrobial therapy in a new cohort of children with cancer and febrile neutropenia (FN) having a demonstrated viral respiratory tract infection., Methods: Prospective, multicenter, noninferiority, randomized study, approved by the ethical committee, in children presenting with FN at seven hospitals in Chile, evaluated at admission for diagnosis of bacterial and viral pathogens. Children who were positive for a respiratory virus, negative for a bacterial pathogen, and had a favourable evolution after 48-72 hours of antimicrobial therapy were randomized to either maintain or withhold antimicrobial therapy. The primary endpoint was the percentage of episodes with an uneventful resolution, whereas the secondary endpoints were days of fever, days of hospitalization, requirement of antimicrobial treatment readministration, sepsis, paediatric intensive care unit admission, and death., Results: A total of 301 of 939 children with FN episodes recruited between March 2021 and December 2023 had a respiratory virus as a unique identified microorganism, of which 139 had a favourable evolution at 48-72 hours and were randomized, 70 to maintain and 69 to withdraw antimicrobial therapy. The median days of antimicrobial therapy was 5 (IQR 3-6) versus 3 (IQR 3-6) days (p < 0.001), with similar frequency of uneventful resolution 66/70 (94%) and 66/69 (96%); relative risk, 1.01; (95% CI, 0.93 to 1.09), absolute risk difference 0.01; (95% CI, -0.05 to 0.08) and similar number of days of fever and days of hospitalization. No cases of sepsis, paediatric intensive care unit admission, or death were reported., Discussion: We validated the strategy of withdrawal antimicrobial therapy in children with FN and viral respiratory tract infection based on clinical and microbiological/molecular diagnostic criteria. This will enable advances in antimicrobial stewardship strategies with a possible future impact on antimicrobial resistance., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. [Microorganisms isolated from blood cultures and resistance profile in children with cancer and high-risk febrile neutropenia. Red PINDA, Chile, 2016-2021].
- Author
-
Valenzuela R, Riquelme C, de la Maza V, Álvarez AM, Contardo V, Ducasse K, Payá E, Claverie X, Venegas M, and Santolaya ME
- Subjects
- Humans, Child, Prospective Studies, Child, Preschool, Chile epidemiology, Female, Male, Drug Resistance, Bacterial, Microbial Sensitivity Tests, Adolescent, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacteria drug effects, Neoplasms microbiology, Febrile Neutropenia microbiology, Febrile Neutropenia drug therapy, Bacteremia microbiology, Bacteremia epidemiology, Bacteremia diagnosis, Blood Culture, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology
- Abstract
Bacteremia is a major cause of morbidity and mortality in patients with cancer and episodes of high-risk febrile neutropenia (HRFN)., Objective: To identify the frequency of microorganisms isolated from blood cultures (BC) and their antimicrobial resistance (R) profile in children with HRFN, compared with the same data from previous studies of the same group., Method: Prospective, multicenter, epidemiological surveillance study of microorganisms isolated from BC in patients under 18 years of age, from 7 PINDA network hospitals, between 2016 and 2021., Results: 284 episodes of HRFN with positive BC were analyzed out of 1091 enrolled episodes (26%). Median age 7.2 years [3.0-12.3]. The main isolates were gram-negative bacilli (GNB) 49.2%, gram-positive cocci (GPC) 43.8%, and fungi 3.6%. The most frequently isolated microorganisms were viridans group Streptococci (VGS) (25.8%), Escherichia coli (19.8%), Pseudomonas spp. (11.2%), Klebsiella spp. (10.9%), and coagulase negative Staphylococci (CoNS) (10.9%). There was an increase in R to third-generation cephalosporins (p = 0.011) in GNB and to oxacillin in CoNS (p = 0.00), as well as a decrease in R to amikacin in non-fermenting GNB (p = 0.02) and to penicillin in VGS (p = 0.04)., Conclusion: VGS is the main agent isolated in BC from pediatric patients with cancer and episodes of HRFN, followed by E. coli, Pseudomonas spp., and Klebsiella spp. Having epidemiological surveillance of microorganisms isolated from BC and their antimicrobial R profile is essential to favor the rational use of antimicrobials.
- Published
- 2024
- Full Text
- View/download PDF
6. Clinical Outcome in Children With Cancer With Two or More Microorganisms Isolated From Blood Cultures During Episodes of Fever and Neutropenia.
- Author
-
Ibáñez C, Torres JP, De La Maza V, Rivera S, Valenzuela R, Simian ME, Payá E, Álvarez AM, Contardo V, Martínez D, Claverie X, and Santolaya ME
- Subjects
- Child, Humans, Chile epidemiology, Blood Culture, Neoplasms complications
- Abstract
Background: Bacterial bloodstream infections are a major cause of morbidity and mortality in children with cancer and episodes of fever and neutropenia (FN). The aim of this study was to evaluate the clinical outcome in children with cancer with 2 or more microorganisms isolated from blood cultures during their episodes of FN., Methods: Between 2016 and 2021, children presenting with high-risk FN, admitted to any of the 6 participating hospitals in Santiago, Chile, were included in this study if they have positive blood cultures. We compared the clinical outcome of children with 2 or more microorganisms versus those with single agent isolation., Results: A total of 1074 episodes of high-risk FN were enrolled in the study period, of which 27% (298) had positive blood cultures and 3% (32) had 2 or more microorganisms isolated from blood cultures. The most frequent identified agents were Viridans group streptococci and Escherichia coli in 20%, followed by Coagulase negative staphylococci in 14%. Children with 2 or more microorganisms presented more days of fever (7 vs. 4 days, P = 0.02), needed longer courses of antimicrobial therapy (16 vs. 14 days, P = 0.04) and had higher mortality at day 30 (13% vs. 1%, P = 0.003)., Conclusions: Children with cancer and FN with 2 or more microorganisms isolated from blood cultures had a worse clinical outcome than children with single agent isolation., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. [Management of episodes of febrile neutropenia in children with cancer. Consensus of the Latin American Society of Pediatric Infectious Diseases 2021].
- Author
-
Santolaya ME, Contardo V, Torres JP, López-Medina E, Rosanova MT, Álvarez AM, Gutiérrez V, Claverie X, Rabello M, Zubieta M, Álvarez-Olmos MI, Camacho G, Perez P, Mariño C, Garces C, Coronell W, López P, Gómez S, and Epelbaum C
- Subjects
- Child, Consensus, Fever, Humans, Latin America, Communicable Diseases, Febrile Neutropenia drug therapy, Neoplasms complications
- Abstract
The Committee for Infections in Immunocompromised Children of Sociedad Latinoamericana de Infectología Pediátrica, presents this Consensus document, titled "Management of episodes of febrile neutropenia in children with cancer. Consensus of the Sociedad Latinoamericana de Infectología Pediátrica 2021". The document includes recommendations on prevention, prediction, diagnosis, treatment and prognosis of episodes of fever and neutropenia, including specific recommendations on: Analysis at admission; evaluation, adjustments and duration of antimicrobial therapies; diagnosis and management of invasive fungal infection; analysis of the main clinical source of infections; environmental conditions necessary for hospitals caring for children with cancer and chemoprophylaxis. Special emphasis has been placed on providing the best recommendations to optimize the management of episodes of fever and neutropenia in children with cancer, with equity and excellence through all the centers that treat these patients in Latin America.
- Published
- 2021
- Full Text
- View/download PDF
8. Cytokine and chemokine profiles in episodes of persistent high-risk febrile neutropenia in children with cancer.
- Author
-
Tapia LI, Olivares M, Torres JP, De la Maza V, Valenzuela R, Contardo V, Tordecilla J, Álvarez AM, Varas M, Zubieta M, Salgado C, Venegas M, Gutiérrez V, Claverie X, Villarroel M, and Santolaya ME
- Subjects
- Child, Febrile Neutropenia diagnosis, Febrile Neutropenia microbiology, Febrile Neutropenia virology, Female, Humans, Male, ROC Curve, Risk Factors, Chemokines blood, Cytokines blood, Febrile Neutropenia blood, Neoplasms blood
- Abstract
Background: In children with cancer and persistent high-risk febrile neutropenia (HRFN), cytokines/chemokines profiles can guide the differentiation of febrile neutropenia (FN) due to infections and episodes of unknown origin (FN-UO)., Methods: A prospective, multicenter study in Santiago, Chile included patients ≤ 18 years with cancer and HRFN. Clinical and microbiological studies were performed according to validated protocols. Serum levels of 38 cytokines/chemokines were determined on day 4 of persistent HRFN. We performed comparisons between i) HRFN episodes with a detected etiological agent (FN-DEA) and FN-UO, and ii) bacterial versus viral infections. ROC curves were used to assess the discriminatory power of the analytes., Results: 110 HRFN episodes were enrolled (median age 8 years, 53% female). Eighty-four patients were FN-DEA: 44 bacterial, 32 viral, and 8 fungal infections. Twenty-six cases were categorized as FN-UO. Both groups presented similar clinical and laboratory characteristics. Nineteen out of 38 analytes had higher concentrations in the FN-DEA versus FN-UO group. G-CSF, IL-6, and Flt-3L showed the highest discriminatory power to detect infection (AUC 0.763, 0.741, 0.701). Serum levels of G-CSF differentiated bacterial infections and IP-10 viral agents. A combination of G-CSF, IL-6, Flt-3L, and IP-10 showed an AUC of 0.839, 75% sensitivity, and 81% specificity., Conclusion: A specific immune response is present on day four of persistent HRFN in children with cancer. We propose a combined measure of serum concentrations of G-CSF, IL-6, IP-10, and Flt-3L, in order to predict the presence of an infectious agent as compared to an episode of FN with unknown origin., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
9. [Clinical and cost characterization of hospitalization associated with varicella in children from the Metropolitan Region and Valparaíso, Chile].
- Author
-
Torres JP, Maza V, Izquierdo G, Contardo V, Conca N, Ducasse K, and Castro M
- Subjects
- Chickenpox Vaccine, Child, Child, Preschool, Chile epidemiology, Female, Hospitalization, Humans, Infant, Male, Multicenter Studies as Topic, Retrospective Studies, Chickenpox complications, Chickenpox epidemiology, Chickenpox prevention & control
- Abstract
Background: Varicella is a relevant infection in Chile and may cause serious complications and death, which could be associated with significant health care resource utilization and associated costs. In Chile, sentinel surveillance is carried out only on an outpatient basis, without knowing the impact of varicella in serious cases who need to be hospitalized., Aim: To describe the clinical characteristics and the costs associated with hospitalized children with diagnosis of varicella prior to the vaccine introduction in the National Immunization Program in Chile., Patients and Methods: A multicenter, observational, and retrospective study in hospitalized children (0-15 years) with a diagnosis of varicella, were conducted in five hospitals in Chile between January 2011 and December 2015. A review of the clinical records was performed to evaluate the clinical characteristics of the disease and costs associated with hospitalization episodes for varicella., Results: A total of 685 hospitalized children for varicella were included in this study. The median age was 3 years (IQR: 1-5), most children were between 1 and 4 years of age (52% of total cases). 56% were male, and only 7 patients (1%) had a history of previous varicella vaccination. The median lenght of days of hospitalization was 3 days (IQR: 2-5). 13% of the cases required hospitalization in a more complex care unit, 6% in the intermediate unit and 7% in the pediatric intensive treatment unit, both with a median stay of 3 days. The main complications were: skin and soft tissue infections (42%), neurologic (8%) and septic or toxic shock (4%). There were 3 cases of death (0.4%). The direct cost of a varicella case was US $ 417, the indirect cost was US $ 224 and the proportional cost of a case of death was US $ 3,575. It is estimated that the total cost of a hospitalized varicella case in Chile was US $ 4,216., Conclusions: Varicella is associated with a significant burden of disease in Chile. The median hospital stay was three days with 13% of cases requiring medical care in a complex unit, with high associated costs which could be significantly reduced with the recently incorporation of the varicella vaccine into the National Immunization Program.
- Published
- 2021
- Full Text
- View/download PDF
10. Multisystem inflammatory syndrome in children (MIS-C): Report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic.
- Author
-
Torres JP, Izquierdo G, Acuña M, Pavez D, Reyes F, Fritis A, González R, Rivacoba C, Contardo V, and Tapia LI
- Subjects
- Adolescent, COVID-19, Child, Child, Preschool, Chile epidemiology, Coronavirus Infections epidemiology, Female, Hospitalization, Humans, Infant, Infant, Newborn, Male, Pandemics, Pneumonia, Viral epidemiology, SARS-CoV-2, Systemic Inflammatory Response Syndrome therapy, Betacoronavirus, Coronavirus Infections complications, Pneumonia, Viral complications, Systemic Inflammatory Response Syndrome epidemiology
- Abstract
Objective: To describe the clinical and epidemiological characteristics of hospitalized children with multisystem inflammatory syndrome in children (MIS-C) in Santiago, Chile., Methods: This was an observational study of children with MIS-C (May 1 to June 24, 2020), in three pediatric hospitals in Santiago. Demographic characteristics and epidemiological data, medical history, laboratory tests, cardiology evaluations, treatment, and clinical outcomes were analyzed., Results: Twenty-seven patients were admitted (median age 6, range 0-14 years). Sixteen of the 27 (59%) required intensive care unit admission; there were no deaths. Seventy-four percent had no comorbidities, and the median number of days of symptoms before admission was 4 (range 2-9 days). Gastrointestinal symptoms were the most frequent, and inflammatory markers were increased at admission. A recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was detected in 82% of cases. The severe group showed significantly lower hemoglobin and albumin levels, decreased platelet counts, and higher d-dimer during disease evolution. Echocardiography showed abnormalities (myocardial, pericardial, or coronary) in 12 patients (46%) during their hospital stay. Anti-inflammatory treatment (immunoglobulin and/or corticosteroids) was prescribed in 24 patients. MIS-C appeared in clusters weeks after the peak of SARS-CoV-2 cases, especially in the most vulnerable areas of Santiago., Conclusions: This study describes the first series (n = 27) of children with MIS-C in a Latin American country, showing favorable clinical outcomes. Education and alerts are required for clinical teams to establish an early diagnosis and prompt treatment., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
11. Usefulness of serum galactomannan in initiating and modifying antifungal therapy in children with cancer and persistent high-risk febrile neutropenia.
- Author
-
Delgado-Araneda M, Valenzuela R, de la Maza V, Rabello M, Álvarez AM, Contardo V, Zubieta M, Gutierrez V, Claverie X, Torres JP, Salgado C, Tordecilla J, Varas M, Avilés CL, Venegas M, Villarroel M, and Santolaya ME
- Subjects
- Aspergillosis drug therapy, Case-Control Studies, Child, Female, Galactose analogs & derivatives, Hematologic Neoplasms complications, Humans, Invasive Pulmonary Aspergillosis drug therapy, Male, Antifungal Agents therapeutic use, Chemotherapy-Induced Febrile Neutropenia complications, Invasive Fungal Infections drug therapy, Mannans blood, Neoplasms complications
- Abstract
Background: Invasive fungal disease is a major cause of morbidity and mortality in children with cancer and high-risk febrile neutropenia (HRFN). Repeated serum galactomannan (sGM) measurements have been described as an effective tool to guide therapy in adults under suspicion of invasive aspergillosis. However, the utility of this approach has not been reported in paediatric population., Objectives: To evaluate the usefulness of sGM measurements in initiating and modifying antifungal therapy (AFT) in children with cancer and persistent HRFN., Patients/methods: Nested case-control study in children with cancer and persistent HRFN episodes, between July 2013 and January 2019. Patients were classified as cases and controls depending on if they received AFT or not, respectively. Through odds ratio analysis, we assessed the role of sGM positivity in the AFT initiation decision. Then, we analysed the group of patients that initiated AFT, and compared those who had AFT modifications and those who did not, analysing different sGM kinetics thresholds., Results: A total of 191 episodes from children with persistent HRFN were enrolled, of which 107 received AFT and 84 did not. The median age was 7 years (IQR 4-12), 52% were male and 89% had a haematologic malignancy as underlying disease. Positive sGM was not associated with AFT initiation (OR 0.99, 95% CI 0.43-2.33, P = .99). A difference threshold in sGM Δ ≥ 0.3 sGM was significantly associated with AFT modification (OR 5.07, 95% CI 1.02- 25.70, P = .04)., Conclusions: Our results suggest the utility of serial sGM sampling during AFT in children with persistent HRFN., (© 2020 Blackwell Verlag GmbH.)
- Published
- 2020
- Full Text
- View/download PDF
12. [Clinical characteristics and microbiological profile of viridans group streptococci bacteremia in children with cancer and high-risk febrile neutropenia].
- Author
-
Cortés D, Maldonado ME, Rivacoba MC, Maza V, Valenzuela R, Payá E, Contardo V, Álvarez AM, Avilés CL, Becker A, Salgado C, Tordecilla J, Varas M, Venegas M, Villarroel M, Viviani T, Zubieta M, and Santolaya ME
- Subjects
- Anti-Bacterial Agents therapeutic use, Child, Chile epidemiology, Humans, Prospective Studies, Bacteremia drug therapy, Febrile Neutropenia drug therapy, Neoplasms complications, Neoplasms drug therapy, Streptococcal Infections drug therapy
- Abstract
Background: Viridans group streptococci (VGS) has acquired relevance as a microorganism causing febrile neutropenia, associated with significant morbidity., Aim: To characterize episodes of bacteremia caused by VGS in children with cancer who developed high-risk febrile neutropenia (HRFN) during the period from April 2004 to June 2018 in six pediatric hospitals of Santiago, Chile., Method: Database analysis of 4 successive, prospective and multicentric studies recording clinical and laboratory characteristics of patients, as well as antimicrobial susceptibility pattern of isolated strains., Results: 95 episodes of VGS bacteremia in 91 children with HRFN were analyzed. It emphasizes acute myeloid leukemia as cancer type, deep neutropenia, prolonged hospitalization (15 days), with extended use of antimicrobials (14 days) and use of cytarabine in chemotherapy schemes (86% episodes). The most frequent clinical manifestations were respiratory and gastrointestinal, associating up to 26% viridans group shock syndrome. There was high resistance to β lactams. As expected, there were not non-susceptible strains to vancomycin., Discussion: VGS is a relevant microorganism in children with cancer, fever and neutropenia, with a high percentage of sepsis. Resistance to β lactams is an issue that requires strict epidemiological surveillance in this population.
- Published
- 2020
- Full Text
- View/download PDF
13. [Young women with HIV infection acquired by vertical transmission: Expectations of having uninfected children].
- Author
-
Villarroel J, Álvarez AM, Salvador F, Chávez A, Wu E, and Contardo V
- Subjects
- Adolescent, CD4 Lymphocyte Count, Drug Therapy, Combination, Female, Follow-Up Studies, Genotype, HIV Infections immunology, HIV Infections prevention & control, Humans, Infant, Newborn, Pregnancy, Pregnancy Complications, Infectious drug therapy, Pregnancy Outcome, Viral Load, Young Adult, Anti-HIV Agents therapeutic use, HIV Infections transmission, Infectious Disease Transmission, Vertical prevention & control, Pregnancy Complications, Infectious virology
- Abstract
Introduction: Pediatric antiretroviral therapy (ART), changed the prognosis of the disease, allowing young women infected by vertical transmission (TV) to be pregnant without risk for their fetus of acquiring this infection., Aim: To describe the clinical-immune status in pregnant women that acquired HV by vertical transmission, treatments received, monitoring of pregnancy and newborn characteristics., Material and Methods: A protocol was performed, evaluating clinical and immunological parameters during pregnancy, ART used, protocol preventing vertical transmission (PPTV), and follow up of children to 18 months of age., Results: Of 358 HIV-positive patients vertically infected, five women became pregnant, between 14 and 24 years old. Pregnancies were controlled in clinical/immune-stage N2 C3. They had received two to five therapies. Full PPTV was performed in all binomials. Pre-natal undetectable viral loads ranged from 4,700 ARN copies/mL. Five living children were born by Caesarean section, four of them with 37 weeks of completed gestation and one of them with 34 weeks of gestation. All received zidovudine (AZT) for 6 weeks. CD4 at 72 hours of life ranged from 48% to 74.6%. All children were born uninfected with HIV. Only two had mild anemia., Conclusions: Expectations of HIV mothers vertically infected to have healthy children are similar to those infected by horizontal transmission, using PPTV.
- Published
- 2016
- Full Text
- View/download PDF
14. Respiratory Viral Infections and Coinfections in Children With Cancer, Fever and Neutropenia: Clinical Outcome of Infections Caused by Different Respiratory Viruses.
- Author
-
Torres JP, De la Maza V, Kors L, Villarroel M, Piemonte P, Izquierdo G, Salgado C, Tordecilla J, Contardo V, Farfán MJ, Mejías A, Ramilo O, and Santolaya ME
- Subjects
- Child, Child, Preschool, Chile epidemiology, Female, Humans, Male, Prospective Studies, Treatment Outcome, Viruses, Coinfection epidemiology, Coinfection virology, Febrile Neutropenia complications, Febrile Neutropenia epidemiology, Neoplasms complications, Neoplasms epidemiology, Respiratory Tract Infections complications, Respiratory Tract Infections epidemiology, Respiratory Tract Infections virology, Virus Diseases complications, Virus Diseases epidemiology, Virus Diseases virology
- Abstract
Background: Respiratory viral infections in episodes of fever and neutropenia (FN) in children with cancer are not well characterized. We compared the clinical outcome of infections caused by different respiratory viruses (RVs) and by RV coinfection in this population., Methods: Children with cancer and FN at 3 hospitals in Chile were prospectively evaluated by clinical examination, blood cultures and detection of 17 RVs using multiplex polymerase chain reaction (nasopharyngeal samples). Clinical characterization and outcome variables were determined and compared by the type of RV detected., Results: A total of 1044 episodes of FN in 525 children were included. At least 1 RV was detected in 46%. In 350 of 1044 (34%) episodes, we detected only RVs, of which 284 (81%) were classified as a single-RV infection and 66 (19%) as a viral coinfection. Respiratory symptoms were present at admission in 65% of the episodes with any detected RV. Median age was 6 years (interquartile range, 3-10), and 51% were women. The most common RVs detected were rhinovirus, respiratory syncytial virus, parainfluenza, influenza, adenovirus and human metapneumovirus. Episodes caused by different types of RVs had no differences in the clinical outcome (days of hospitalization, days of fever, O2 requirement, admission to the intensive care unit and death) and when comparing single and viral coinfection., Conclusions: To our knowledge, this is the largest report comparing clinical outcome in FN episodes caused by different RVs in children with cancer. A positive polymerase chain reaction for RV at admission was significantly associated with the presence of respiratory symptoms. Our data showed a favorable outcome in all episodes with RV detection, including single and viral coinfections.
- Published
- 2016
- Full Text
- View/download PDF
15. [Pott's disease and immunological diagnosis of tuberculosis, about a pediatric clinical case].
- Author
-
Contardo V, Cofré J, and Hernández P
- Subjects
- Child, Discitis diagnosis, Enzyme-Linked Immunospot Assay, Humans, Immunologic Tests, Lumbar Vertebrae, Male, Mycobacterium tuberculosis isolation & purification, Psoas Abscess diagnosis, Tuberculin Test, Tuberculosis, Spinal diagnosis
- Abstract
Unlabelled: Tuberculosis (TB) remains a major health problem in the world. The clinical forms of TB in children are variable, pulmonary involvement occurs in two thirds of cases. In the remaining third, clinical forms incluye node, meningeal and osteoarticular involvement., Case Report: 7 year old boy with a history of an osteolytic lesion of the right ischial branch. Three months later he presented with spondylodiscitis at L2-L3, associated with a large abscess in the right iliac psoas muscle. Pott's disease was suspected, and tuberculin test and T-SPOT®.TB test were performed, with a positive result. Antimicrobial treatment was initiated with isoniazid, rifampicin, pyrazinamide and ethambutol. After 30 days, Mycobacterium tuberculosis was isolated from psoas abscess. We discuss methods of TB diagnosis, with special emphasis on immunological methods: tuberculin test and interferon-gamma release assays. Methods of immunological TB diagnosis are an important contribution to the diagnosis of this disease, allowing early initiation of treatment.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.